DexCom reiterates $5.16B-$5.25B 2026 revenue outlook while raising operating margin to 23%-23.5%

Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter ...
Drug Delivery Business

Dexcom stock dips after hours despite Q1 beats, 15% sales growth

Dexcom (Nasdaq:DXCM) today posted first-quarter financial results that came in ahead of the Wall Street forecast.
San Diego Union-Tribune

Dexcom starts selling its new over-the-counter glucose monitor. Here’s how much it costs

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Hosted on MSN

DexCom lifts 2026 operating margin outlook to 23%-23.5%

DexCom boosted its 2026 non-GAAP operating margin guidance to 23%-23.5% after reporting strong Q1 revenue growth and product momentum. Management credited expanded coverage for type 2 non-insulin ...
The Motley Fool

Where Will DexCom Be in 5 Years?

DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

Dexcom Reports First Quarter 2026 Financial Results

(Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. First Quarter 2026 Fin ...
Business Wire

Dexcom Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024 at 4:30 p.m. Eastern Time.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2024 financial results after market close on Thursday, October 24, 2024. Management ...
Seeking Alpha

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...
Business Wire

Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes

Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...
Nasdaq

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...